Needham Reiterates Buy on Medtronic, Maintains $120 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.6%

Neg 0% Neu 86.6% Pos 0%

Needham analyst Mike Matson reiterates Medtronic (NYSE:MDT) with a Buy and maintains $120 price target.

Comments

No comments yet. Be the first!